Cargando…
Risks of metabolic syndrome in the ADVANCE and NAMSAL trials
INTRODUCTION: The ADVANCE and NAMSAL trials evaluating antiretroviral drugs have both reported substantial levels of clinical obesity in participants. As one of the main risk factors for metabolic syndrome, growing rates of obesity may drive metabolic syndrome development. This study aims to evaluat...
Autores principales: | Tovar Sanchez, Tamara, Mpoudi-Etame, Mireille, Kouanfack, Charles, Delaporte, Eric, Calmy, Alexandra, Venter, Francois, Sokhela, Simiso, Bosch, Bronwyn, Akpomiemie, Godspower, Tembo, Angela, Pepperrell, Toby, Simmons, Bryony, Casas, Carmen Perez, McCann, Kaitlyn, Mirchandani, Manya, Hill, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544962/ https://www.ncbi.nlm.nih.gov/pubmed/37791109 http://dx.doi.org/10.3389/frph.2023.1133556 |
Ejemplares similares
-
Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa
por: Sokhela, Simiso, et al.
Publicado: (2022) -
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)
por: Bousmah, Marwân-al-Qays, et al.
Publicado: (2020) -
Phase 3 trials of new antiretrovirals are not representative
of the global HIV epidemic
por: Pepperrell, Toby, et al.
Publicado: (2020) -
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
por: Sokhela, Simiso, et al.
Publicado: (2022) -
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)